Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Depreciation & Amortization (CF) (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Depreciation & Amortization (CF) data on record, last reported at $32000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 3.03% year-over-year to $32000.0; the TTM value through Sep 2025 reached $129000.0, down 28.73%, while the annual FY2024 figure was $129000.0, 71.33% down from the prior year.
  • Depreciation & Amortization (CF) reached $32000.0 in Q3 2025 per ASMB's latest filing, roughly flat from $32000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $134000.0 in Q3 2022 and bottomed at $32000.0 in Q1 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $86315.8, with a median of $116000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): increased 12.61% in 2022, then tumbled 74.6% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $120000.0 in 2021, then rose by 3.33% to $124000.0 in 2022, then crashed by 32.26% to $84000.0 in 2023, then crashed by 61.9% to $32000.0 in 2024, then changed by 0.0% to $32000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $32000.0 in Q3 2025, $32000.0 in Q2 2025, and $33000.0 in Q1 2025.